Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastische middelen - behandeling van borstkanker, speciale vormen van longkanker (niet-kleincellige longkanker), prostaatkanker, maagkanker of kanker van het hoofd en de nek.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotische middelen - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - clopidogrelbesilaat samenstelling overeenkomend met ; clopidogrel - filmomhulde tablet - cellulose, microkristallijn (e 460) ; citroenzuur 1-water (e 330) ; crospovidon (e 1202) ; glyceroltriacetaat (e 1518) ; hyprolose (e 463) ; hypromellose (e 464) ; ijzeroxide rood (e 172) ; lactose 1-water ; macrogol 6000 ; mannitol (d-) (e 421) ; stearinezuur (e 570) ; talk (e 553 b) ; titaandioxide (e 171), - clopidogrel

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - multiple myeloma - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - emtricitabine, tenofovir disoproxil maleate - hiv-infecties - antivirale middelen voor systemisch gebruik - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 en 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 en 5.

Den europeiske union - nederlandsk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - pregabaline - anxiety disorders; epilepsy - van anti-epileptica, - neuropathische painpregabalin mylan is geïndiceerd voor de behandeling van perifere en centrale neuropathische pijn bij volwassenen. epilepsypregabalin mylan wordt aangeduid als adjuvante therapie bij volwassenen met partiële epilepsie met of zonder secundaire veralgemening. gegeneraliseerde angst disorderpregabalin mylan is geïndiceerd voor de behandeling van de gegeneraliseerde angststoornis (gad) bij volwassenen.

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - abacavirhydrochloride 1-water 714,2 mg/stuk samenstelling overeenkomend met ; abacavir 600 mg/stuk ; lamivudine 0-water 300 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), cellulose, microkristallijn (e 460) ; crospovidon (e 1202) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171) ; zonnegeel fcf aluminiumlak (e 110), - lamivudine and abacavir

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - brimonidinetartraat 2 mg/ml samenstelling overeenkomend met ; brimonidine 1,32 mg/ml - oogdruppels, oplossing - benzalkoniumchloride ; citroenzuur 1-water (e 330) ; natriumchloride ; natriumhydroxide (e 524) ; polyvinylalcohol (e 1203) ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; zoutzuur (e 507), benzalkoniumchloride ; citroenzuur 1-water (e 330) ; natriumchloride ; natriumhydroxide (e 524) ; polyvinylalcohol (e1203) ; trinatriumcitraat 2-water (e 331) ; water, gezuiverd ; zoutzuur (e 507), - brimonidine

Nederland - nederlandsk - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

mylan b.v. dieselweg 25 3752 lb bunschoten - etoricoxib 120 mg/stuk - filmomhulde tablet - calciumwaterstoffosfaat 0-water (e 341) ; carnaubawas (e 903) ; cellulose, microkristallijn (e 460(i)) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; indigokarmijn aluminiumlak (e 132) ; lactose 1-water ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; titaandioxide (e 171), calciumwaterstoffosfaat 0-water (e 341) ; carnaubawas (e 903) ; cellulose, microkristallijn (e 460) ; croscarmellose natrium (e 468) ; glyceroltriacetaat (e 1518) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; indigokarmijn aluminiumlak (e 132) ; lactose 1-water ; magnesiumstearaat (e 470b) ; siliciumdioxide (e 551) ; titaandioxide (e 171), - etoricoxib